Groundbreaking Covid study with Hispanics, Blacks, Native Americans shows varied results with Genentech drug
The 389-person clinical trial, which used the rheumatoid arthritis drug Actemra in patients with Covid-associated pneumonia, is part of a "call to action" for more-inclusive drug studies. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 18, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Groundbreaking Covid study with Hispanics, Blacks, Native Americans shows varied results with Genentech drug
The 389-person clinical trial, which used the rheumatoid arthritis drug Actemra in patients with Covid-associated pneumonia, is part of a "call to action" for more-inclusive drug studies. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 18, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Roche ’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III EMPACTA study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Actemra ®/RoActemra® (tocilizumab) plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care (log-rank p-value = 0.0348; HR [95% CI] = 0.56 [0.32, 0.97]). The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra/RoActemra arm versus 19.3% in the placebo...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III EMPACTA study met its primary endpoint, showing that patients with COVID-19 associated pneumonia who received Actemra ®/RoActemra® (tocilizumab) plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care (log-rank p-value = 0.0348; HR [95% CI] = 0.56 [0.32, 0.97]). The cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra/RoActemra arm versus 19.3% in the placebo...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Efficacy and Safety of Tocilizumab in Takayasu Arteritis Efficacy and Safety of Tocilizumab in Takayasu Arteritis
Results from a phase 3 trial show that long-term treatment with tocilizumab is a safe and effective option for refractive Takayasu arteritis.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 16, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

ICMR reviewing use of tocilizumab for treatment of coronavirus pandemic
Tocilizumab is a rheumatoid arthritis drug manufactured by Swiss pharmaceutical company Roche under the brand name Actemra. The medication is part of the health ministry ’s clinical management protocol for Covid-19 under investigational therapies for patients with moderate symptoms of the illness. (Source: The Economic Times)
Source: The Economic Times - September 8, 2020 Category: Consumer Health News Source Type: news

Arthritis drug may help coronavirus patients by calming deadly inflammatory cytokine storms
A new study found that tocilizumab helped decrease levels of PAI-1, a protein which causes small blood clots in vessels throughout the body, including the lungs, in coronavirus patients. (Source: the Mail online | Health)
Source: the Mail online | Health - August 31, 2020 Category: Consumer Health News Source Type: news

DILI Associated With Tocilizumab in a Patient With COVID-19 DILI Associated With Tocilizumab in a Patient With COVID-19
This case report warns of a rare but potentially serious hepatotoxicity associated with the IL-6 receptor antagonist tocilizumab, administered to a patient with COVID-19 to treat cytokine storm.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

RA Infection Risk With Abatacept, Rituximab and Tocilizumab RA Infection Risk With Abatacept, Rituximab and Tocilizumab
How common are infections among rheumatoid arthritis patients receiving treatment with these non-TNF-inhibitors?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Tocilizumab may improve survival in sickest COVID-19 patients, scientists say
Among other treatments, they said tocilizumab was considered for off-label usage for the patients whose respiratory symptoms were declining -- many of whom were requiring mechanical ventilator support. In the observational study, the researchers noted that 210 patients received tocilizumab, and the other 420 did not. (Source: The Economic Times)
Source: The Economic Times - August 21, 2020 Category: Consumer Health News Source Type: news

Observational study identifies drug that improves survival in sickest COVID-19 patients
Researchers at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, have utilized its statewide observational database of more than 5,000 hospitalized COVID-19 patients to show that a drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU). (Source: World Pharma News)
Source: World Pharma News - August 19, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Observational study identifies drug that improves survival in sickest COVID-19 patients
(Hackensack Meridian Health) A drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU). The findings were published in The Lancet Rheumatology on Aug. 14, and Hackensack Meridian Health researchers have updated the U.S. Food and Drug Administration and other national leaders of the findings to potentially accelerate improved outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 19, 2020 Category: Cancer & Oncology Source Type: news

Tocilizumab for giant cell arteritis (GCA) during the COVID-19 pandemic (RPS 2007), version 1: 30 July 2020, NHS England and NHS Improvement
In response to the public health emergency posed by coronavirus disease 2019 (COVID-19), NHS England and NHS Improvement have established a rapid policy development process to aid clinicians in offering best care and advice to patients with or at risk of COVID-19. This document sets out the recommendations for the use of tocilizumab in giant cell arteritis (GCA) in the context of COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 13, 2020 Category: Consumer Health News Source Type: news

Drug vignettes: Tocilizumab, CEBM
Patients with severe COVID-19 can develop cytokine release syndrome ( “cytokine storm”) and are 2 External 0 0 0 reported false https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2.full.pdf true false%> to have high circulating IL-6 concentrations. Tocilizumab is a recombinant humanized anti-human IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R). It has therefore been proposed to be of value in the management of severe COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 5, 2020 Category: Consumer Health News Source Type: news

Coronavirus: Tocilizumab doesn't work on infection, say studies
Doctors in New Jersey have said there is no evidence to support the use of tocilizumab, marketed as Actemra, to manage the often fatal cytokine storm seen in Covid-19 patients. (Source: the Mail online | Health)
Source: the Mail online | Health - August 4, 2020 Category: Consumer Health News Source Type: news

Better outcomes in severe COVID-19 patients administered interleukin-6 inhibitors early
(Boston Medical Center) New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses. The treatment was more effective when administered earlier in the disease course and reduced mortality rates and the need for intubation. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 4, 2020 Category: Biology Source Type: news

Tocilizumab ± methotrexate not a cost-effective option in early RA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2020 Category: Drugs & Pharmacology Source Type: news

Tocilizumab for giant cell arteritis (GCA) during the COVID-19 pandemic (RPS 2007), NHS England (published 29th July 2020)
This interim policy proposition provides an option for some patients on tocilizumab for GCA nearing the end of their prescription to continue past 12 months up to April 2021. The basis for this is reducing the risk of a flare up of the disease in a vulnerable group of patients in the context of COVID-19. A flare up would lead to hospital interactions and high dose steroid medication, both of which may increase the risk and severity of COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 30, 2020 Category: Consumer Health News Source Type: news

Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia
Basel, 29 July - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III COVACTA study of Actemra ®/RoActemra® (tocilizumab) did not meet its primary endpoint of improved clinical status in hospitalised adult patients with severe COVID-19 associated pneumonia. In addition, the key secondary endpoints, which included the difference in patient mortality at week four, were not met; however, there was a positive trend in time to hospital discharge in patients treated with Actemra/RoActemra. The COVACTA study did not identify any new safety signals for Actemra/RoActemra. Further analysis of the trial resul...
Source: Roche Media News - July 29, 2020 Category: Pharmaceuticals Source Type: news

Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia
Basel, 29 July - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III COVACTA study of Actemra ®/RoActemra® (tocilizumab) did not meet its primary endpoint of improved clinical status in hospitalised adult patients with severe COVID-19 associated pneumonia. In addition, the key secondary endpoints, which included the difference in patient mortality at week four, were not met; however, there was a positive trend in time to hospital discharge in patients treated with Actemra/RoActemra. The COVACTA study did not identify any new safety signals for Actemra/RoActemra. Further analysis of the trial resul...
Source: Roche Investor Update - July 29, 2020 Category: Pharmaceuticals Source Type: news

Health ministry asks DGCI to ensure equitable distribution of Remdesivir, Tocilizumab drugs
The ministry has shot off a letter to the Drugs Controller General of India (DCGI), asking it to ascertain how many states and Union territories (UTs) have been covered and which of them are left, as far as the availability and distribution of these drugs by the respective companies is concerned. (Source: The Economic Times)
Source: The Economic Times - July 29, 2020 Category: Consumer Health News Source Type: news

Arthritis anti-inflammatory treatment could halt immune system 'storm' to coronavirus
Doctors say anti-inflammatory treatment tocilizumab could save lives by halting the immune system 'storm' that has killed thousands of virus patients. (Source: the Mail online | Health)
Source: the Mail online | Health - July 28, 2020 Category: Consumer Health News Source Type: news

Kenya: Kenyan Patients Enrolled On Clinical Trial for Coronavirus-Related Pneumonia Treatment
[Capital FM] Nairobi -- Pharmaceutical firm Roche on Tuesday announced the enrollment of Kenyan patients on a clinical trial to evaluate the efficacy of tocilizumab drug for coronavirus-related pneumonia. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 21, 2020 Category: African Health Source Type: news

Indiscriminate use led to bogus tocilizumab injections: FDCA
The patented drug is manufactured only by Switzerland-based Roche Pharma and marketed in India by Cipla, he said, adding that since May, as many as 6,400 tocilizumab injections have so far been imported in Gujarat. (Source: The Economic Times)
Source: The Economic Times - July 19, 2020 Category: Consumer Health News Source Type: news

Survival Up With Tocilizumab in Ventilated COVID - 19 Patients
More patients have superinfections with tocilizumab, but superinfection does not affect case fatality rate (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - July 15, 2020 Category: Respiratory Medicine Tags: Infections, Nursing, Pharmacy, Pulmonology, Critical Care, Journal, Source Type: news

Survival Up With Tocilizumab in Ventilated COVID-19 Patients
WEDNESDAY, July 15, 2020 -- For patients with COVID-19 requiring mechanical ventilation, tocilizumab is associated with improved survival, according to a study published online July 11 in Clinical Infectious Diseases. Emily C. Somers, Ph.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 15, 2020 Category: Pharmaceuticals Source Type: news

COVID-19: Patients improve after immune-suppressant treatment
(Cedars-Sinai Medical Center) Most patients hospitalized with COVID-19 (coronavirus) pneumonia experienced improvement after receiving a Food and Drug Administration-approved drug normally given for rheumatoid arthritis, according to an observational study at Cedars-Sinai. Outcomes for patients who received the drug, tocilizumab, included reduced inflammation, oxygen requirements, blood pressure support and risk of death, compared with published reports of illness and death associated with severely ill COVID-19 patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2020 Category: International Medicine & Public Health Source Type: news

Remdesivir makers told to ramp up production by the department of pharmaceuticals
Delhi ’s state regulator has written to chemists' association also about illegal imports of Covid-related drugs remdesivir, favipiravir and tocilizumab from Bangladesh. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 14, 2020 Category: Pharmaceuticals Source Type: news

Biocon to take on Roche Pharma with its psoriasis drug to treat moderate to severe Covid patients
​​The company is marketing the drug as a replacement to Roche’s tocilizumab (originally approved for rheumatoid arthritis) that is currently in off-label use among Covid-19 patients who suffer from cytokine release syndrome (CRS). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 14, 2020 Category: Pharmaceuticals Source Type: news

Biocon defends limited trial patients for Itolizumab nod, says followed science of "highest order"
The company is marketing the drug as a replacement to Roche Pharma ’s Tocilizumab (originally approved for rheumatoid arthritis) that is currently in off label use (it means use of a drug for an unapproved indication) among Covid-19 patients who suffer from cytokine release syndrome (CRS) or “cytokine storm”. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 13, 2020 Category: Pharmaceuticals Source Type: news

'Indiscriminate use of remdesivir, tocilizumab on COVID patients can cause more harm than good'
The ICMR strongly recommended that the focus of clinical management should continue to remain on oxygen therapy, steroids which are widely available and inexpensive, appropriate and timely administration of anti-coagulants and high quality supportive care, including mental health counselling for patients and families, the ministry said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 11, 2020 Category: Pharmaceuticals Source Type: news

Tocilizumab Therapy Tied to Better Outcomes of Severe COVID-19 Tocilizumab Therapy Tied to Better Outcomes of Severe COVID-19
Tocilizumab therapy is associated with a lower risk of invasive mechanical ventilation or death in patients with severe COVID-19, according to a new study.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - July 7, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Sanofi halts trials of IL-6 drug for Covid-19, India to continue with trial of another drug of similar class
The decision casts a shadow on other similar classes of drugs such as Tocilizumab by Swiss drug maker Roche pharma, that are under trial for treating Covid-19 in countries including India. However, the investigator leading the Tocilizumab trial in India told ET that the efficacy of these drugs on moderate Covid-19 patients still needs to be studied. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 7, 2020 Category: Pharmaceuticals Source Type: news

Tocilizumab Shows Promise for Treatment of COVID-19
WEDNESDAY, June 24, 2020 -- Use of tocilizumab to target cytokine release syndrome (CRS) seems beneficial for patients with COVID-19, according to a study published online June 15 in CHEST. Christina C. Price, M.D., from the Yale University School... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 24, 2020 Category: Pharmaceuticals Source Type: news

Tocilizumab Might Help Curb Severe COVID-19
TUESDAY, June 23, 2020 -- Could a drug used in cancer treatment spare hospital patients from the ravages of severe COVID-19? Yale doctors think it can after giving the medication, known as tocilizumab, to severely ill patients back in March. How... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 23, 2020 Category: General Medicine Source Type: news

Repurposed drug shows promise for treating COVID-19 inflammation
Yale clinicians report promising results after treating COVID-19 with the drug tocilizumab, which is known to reduce inflammation in chemotherapy patients. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 18, 2020 Category: Universities & Medical Training Source Type: news

U.K. Researchers Say They Have Found First Drug that Improves COVID-19 Survival
Researchers in England say they have the first evidence that a drug can improve COVID-19 survival: A steroid called dexamethasone reduced deaths by up to one third in severely ill hospitalized patients. Results were announced Tuesday and researchers said they would publish them soon. The study is a large, strict test that randomly assigned 2,104 patients to get the drug and compared them with 4,321 patients getting only usual care. The drug was given either orally or through an IV. It reduced deaths by 35% in patients who needed treatment with breathing machines and by 20% in those only needing supplemental oxygen. It did ...
Source: TIME: Science - June 16, 2020 Category: Science Authors: MARILYNN MARCHIONE /AP Tags: Uncategorized Source Type: news

Remdesivir, tocilizumab being considered for 'restricted use' on severely ill COVID-19 patients
The much-touted anti-malarial drug hydroxychloroquine will continue to be used while azythromycin may be dropped from the treatment protocol, sources in the know of the developments told . (Source: The Economic Times)
Source: The Economic Times - June 11, 2020 Category: Consumer Health News Source Type: news

Arthritis drug reduced the risks of dying of coronavirus by nearly half in a small study
A new study from the University of Michigan found that tocilizumab, a rheumatoid arthritis drug, reduced the liklihood of death for coronavirus patients on ventilators by 45%. (Source: the Mail online | Health)
Source: the Mail online | Health - June 4, 2020 Category: Consumer Health News Source Type: news

Roche ’s Elecsys IL-6 test receives FDA Emergency Use Authorisation to help in identifying patients at high risk of severe inflammatory response
             Basel, 04 June 2020   - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorisation (EUA) for the Elecsys® IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and can be used to help identify patients with confirm ed COVID-19 disease who could be at high risk of intubation with mechanical ventilation. The test can support physicians, in combination with other examinations and vital signs, to decide early on if a patient with confirmed...
Source: Roche Media News - June 4, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Elecsys IL-6 test receives FDA Emergency Use Authorisation to help in identifying patients at high risk of severe inflammatory response
             Basel, 4 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorisation (EUA) for the Elecsys ® IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and can be used to help identify patients with confirmed COVID-19 disease who could be at high risk of intubation with mechanical ventilation. The test can support physicians, in combination with other examinations and vital signs, to decide early on if a patient with confirmed COVID-1...
Source: Roche Investor Update - June 4, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Elecsys IL-6 test receives FDA Emergency Use Authorization to help in identifying patients at high risk of severe inflammatory response
             Basel, 04 June 2020   - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the Elecsys® IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and can be used to help identify patients with confirm ed COVID-19 disease who could be at high risk of intubation with mechanical ventilation. The test can support physicians, in combination with other examinations and vital signs, to decide early on if a patient with confirmed...
Source: Roche Media News - June 4, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Elecsys IL-6 test receives FDA Emergency Use Authorization to help in identifying patients at high risk of severe inflammatory response
             Basel, 4 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the Elecsys ® IL-6 test. This test measures levels of the biomarker interleukin 6 (IL-6) and can be used to help identify patients with confirmed COVID-19 disease who could be at high risk of intubation with mechanical ventilation. The test can support physicians, in combination with other examinations and vital signs, to decide early on if a patient with confirmed COVID-1...
Source: Roche Investor Update - June 4, 2020 Category: Pharmaceuticals Source Type: news

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc. (Source: World Pharma News)
Source: World Pharma News - May 28, 2020 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
      ·Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra ®/RoActemra® (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer. (Source: Roche Investor Update)
Source: Roche Investor Update - May 28, 2020 Category: Pharmaceuticals Source Type: news

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
Basel, 28 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc.   (Source: Roche Media News)
Source: Roche Media News - May 28, 2020 Category: Pharmaceuticals Source Type: news

Dilemma for doctors as Roche ’s Covid drug is ‘life-saver’ but too costly
In India, the drug sold under the brand name Actemra, is approved for the use in autoimmune disease such as rheumatoid arthritis and for six months treatment it costs Rs 2.5 lakh. For Covid-19 patients who are administered this drug, the cost is Rs 60,000 per dosage. (Source: The Economic Times)
Source: The Economic Times - May 20, 2020 Category: Consumer Health News Source Type: news

Dilemma for doctors as Roche ’s experimental drug for Covid-19 is ‘life-saver’ but too costly
In India, the drug sold under the brand name Actemra, is approved for the use in autoimmune disease such as rheumatoid arthritis and for six months treatment it costs Rs 2.5 lakh. For Covid-19 patients who are administered this drug, the cost is Rs 60,000 per dosage. (Source: The Economic Times)
Source: The Economic Times - May 20, 2020 Category: Consumer Health News Source Type: news

COVID-19 news from Annals of Internal Medicine
(American College of Physicians) Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient with COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 18, 2020 Category: Infectious Diseases Source Type: news